U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt

Gilead Sciences

Market Cap: US$166.7b

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Illumina

Market Cap: US$28.2b

Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

Exelixis

Market Cap: US$14.1b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

ACADIA Pharmaceuticals

Market Cap: US$4.4b

A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

ADMA Biologics

Market Cap: US$2.0b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Innoviva

Market Cap: US$1.6b

Operates as a biopharmaceutical company in the United States and internationally.

Theravance Biopharma

Market Cap: US$877.5m

A biopharmaceutical company, develops and commercializes medicines in the United States.

CorMedix

Market Cap: US$660.6m

A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

Elite Pharmaceuticals

Market Cap: US$418.2m

A specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals.

Abeona Therapeutics

Market Cap: US$399.0m

A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.

Compugen

Market Cap: US$224.2m

A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.

Oramed Pharmaceuticals

Market Cap: US$164.9m

Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

Vaxart

Market Cap: US$124.3m

A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.